Clinical trials: Patient Discharge
Dyslipidemias
A Clinical Pharmacology Study of K-877 Controlled Release Tablet
A study to compare the efficacy, safety, and pharmacokinetics of K-877 controlled release tablets with a current normal K-877 tablet in dyslipidemia.
- Trial name
- NCT04079530
- Testing
- K-877 IR 0.2 mg/day, K-877 CR 0.4 mg/day, K-877 CR 0.8 mg/day
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Kowa Company, Ltd.
Parkinson Disease
Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients
To determine if there is any difference in the presence of retinal deterioration in PD patients treated with pramipexole IR versus ropinirole as monitored by comprehensive ophthalmologic assessments from baseline to the end of…
- Trial name
- NCT00144300
- Testing
- Mirapex, Requip
- Where
- 21 sites in United States
- Volunteers
- 246 people
- Sponsor
- Boehringer Ingelheim
Postoperative Pain
A Pharmacokinetic (PK) Study of Extended-Release Epidural Morphine in Upper Abdominal Surgery
The primary purpose of this study is to evaluate the effects of lidocaine/epinephrine test dose administration on the PK profile of a single epidural dose of DepoDur (extended-release epidural morphine) in patients undergoing…
- Trial name
- NCT00728832
- Testing
- DepoDur (extended-release epidural morphine)
- Volunteers
- 39 people
- Sponsor
- EKR Therapeutics, Inc
Healthy
Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients
Randomized, inpatient, ascending multiple dose study given to subjects with schizophrenia and schizoaffective disorder to assess safety and tolerability.
- Trial name
- NCT00581243
- Testing
- SLV-313 SR
- Volunteers
- 32 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pain, Postoperative
An Efficacy and Safety Study to Compare Fentanyl Ionsys and Routine Care With Intravenous (IV) Morphine Patient-controlled Analgesia (PCA) in Participants Who Have Undergone Elective Major Abdominal or Orthopedic Surgery
The purpose of this study is to evaluate the mobilization characteristics, clinical use, safety and Ease of Care (EOC) of a fentanyl Iontophoretic Transdermal Patient Controlled Analgesia (PCA) system (Ionsys) and morphine…
- Trial name
- NCT00766506
- Testing
- Fentanyl IONSYS, Morphine IV PCA
- Where
- 7 sites in United Kingdom
- Volunteers
- 108 people
- Sponsor
- Janssen-Cilag Ltd.
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of two dosages of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute episode of schizoaffective disorder.
- Trial name
- NCT00397033
- Testing
- Paliperidone ER
- Volunteers
- 316 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
The purpose of the study is to evaluate the efficacy, safety, and tolerability of different dose regimens of TV-46000 administered subcutaneously (SC) as compared to placebo during maintenance treatment in adult and adolescent…
- Trial name
- RISE (NCT03503318)
- Testing
- TV-46000
- Where
- 81 sites in United States, Bulgaria
- Volunteers
- 544 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Pain
Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate/Acetaminophen Immediate-Release Tablets in Participants With Moderate to Severe Pain Following Bunionectomy
The primary objective of this study is to evaluate the analgesic efficacy of hydrocodone bitartrate/acetaminophen immediate-release tablets at doses of 5.0 milligrams (mg)/325 mg, 7.5 mg/325 mg, and 10 mg/325 mg every 4 to 6…
- Trial name
- NCT02487108
- Testing
- TV-46763
- Where
- 8 sites in United States
- Volunteers
- 569 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Major Depressive Disorder
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
To evaluate the efficacy of quetiapine fumarate sustained release (Seroquel SR™) in combination with an antidepressant versus an antidepressant alone in patients with Major Depressive Disorder.
- Trial name
- ONYX (NCT00351910)
- Testing
- Quetiapine, Amitriptyline, Bupropion
- Where
- 72 sites in Australia, Belgium and 10 more
- Volunteers
- 494 people
- Sponsor
- AstraZeneca
Chronic Venous Disease, Vein Disease
Randomized, Placebo-crontrolled Clinical Trial Evaluating the Efficacy and Safety of Heparan Sulfate 120 mg Prolonged-Release Tablets Compared With Placebo in Patients With Chronic Venous Disease
This multicenter, randomized, double-blind study is a phase III evaluates the safety and effectiveness of CLR prolonged-release tablets in patients with chronic venous insufficiency, has been shown to be effective in reducing the…
- Conditions
- Chronic Venous Disease, Vein Disease, Venous Insufficiency of Leg
- Trial name
- CLR-18 (NCT07684833)
- Testing
- CLR Tablets - Heparan Sulphate
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Barbara Maglione
Pain
Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain
The purpose of this study is to evaluate the effectiveness and safety of Osmotic Release Oral System (OROS) hydromorphone using standardized conversion from prior opioid therapy among participants with cancer pain.
- Trial name
- NCT01648699
- Testing
- Osmotic Release Oral System (OROS) hydromorphone
- Volunteers
- 20 people
- Sponsor
- Janssen Pharmaceutica
Neurogenic Urinary Bladder Disorder, Urinary Bladder, Neurogenic
Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity
The purpose of this clinical study is to compare efficacy and safety of propiverine hydrochloride extended and immediate release formulations in patients suffering from neurogenic detrusor overactivity.
- Conditions
- Neurogenic Urinary Bladder Disorder, Urinary Bladder, Neurogenic, Bladder Disorder, Neurogenic, Urinary Bladder Disorder, Neurogenic
- Trial name
- NCT01530620
- Testing
- Propiverine hydrochloride ER (extended release), Propiverine hydrochloride IR (immediate release)
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- APOGEPHA Arzneimittel GmbH
COVID-19
101-PGC-005 for the Treatment of COVID-19
This is a prospective, randomized, comparative, multi-centric, adaptive design clinical study to evaluate efficacy, safety, and tolerability of 101-PGC-005 ('005) when used alongside standard of care (SOC) for the treatment of…
- Trial name
- NCT05656521
- Testing
- 101-PGC-005, Dexamethasone
- Where
- 5 sites in India
- Volunteers
- 62 people
- Sponsor
- 101 Therapeutics
Bipolar Depression
Quetiapine Efficacy in Bipolar Depression Study
To reassure the clinical study data on Seroquel antidepressant efficacy in patients who are diagnosed as bipolar depression
- Trial name
- QUEEN (NCT00523601)
- Where
- 3 sites in South Korea
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Breast Cancer
Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®
This is a multicenter, randomized, open-label, active comparator-controlled phase Ⅲ trial to compare efficacy and safety of Goserelin Acetate Sustained-Release Microspheres for Injection (LY01005) and ZOLADEX® in patients with…
- Trial name
- NCT05110170
- Testing
- LY01005, ZOLADEX® 3.6 mg
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Luye Pharma Group Ltd.
Prostate Cancer
Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
This is a randomized, open-label and parallel phase I study to compare pharmacokinetics (PK), pharmacodynamics (PD) and safety of goserelin acetate sustained-release microspheres for injection (LY01005) and ZOLADEX® following…
- Trial name
- NCT05140512
- Testing
- LY01005, ZOLADEX® 3.6 mg
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Luye Pharma Group Ltd.
Hyperlipidemia, Dyslipidemia
Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia
The purpose of this study is to compare the efficacy of NK-104-CR with Placebo and Livalo® on the reduction of LDL-C and to evaluate the safety of NK-104-CR in patients with primary hyperlipidemia or mixed dyslipidemia
- Trial name
- NCT02670434
- Testing
- NK-104-CR, Livalo
- Where
- 45 sites in United States
- Sponsor
- Kowa Research Institute, Inc.
Body Weight Changes
Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide
To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on 24-hour sodium excretion.
- Trial name
- NCT03509545
- Testing
- CHF Patients: ER Torsemide 40 mg, CHF Patients: Furosemide 40 mg
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Restless Legs Syndrome
Restless Legs Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole And The Effect Of Food
This study in RLS patients is designed to assess the affect food has on the absorption, distribution, metabolism and excretion of ropinirole (by dosing some patients in the fasted state and other patients following a high-fat…
- Trial name
- NCT00419692
- Testing
- Ropinirole
- Where
- 2 sites in Germany, South Africa
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Ulcerative Colitis
(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis
The purpose of this study is to compare Budesonide MMX™ 6 mg and Budesonide MMX™ 9 mg tablets to placebo and to Asacol 6x 400 mg tablets over an 8-week treatment period to determine if Budesonide MMX™ is effective in the…
- Trial name
- NCT00679432
- Testing
- Blood sampling, endoscopy, budesonide-MMX® 6 mg, budesonide-MMX® 9 mg
- Where
- 105 sites in United States, Canada and 2 more
- Volunteers
- 510 people
- Sponsor
- Bausch Health Americas, Inc.